Wellgistics Health secures preferred EBV pricing via Kare PharmTech revenue-share deal

Wellgistics Health, Inc.

Entered Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC on March 6, 2026 for product 'KARE Verify' (insurance eligibility & benefits verification).
Revenue split: 50% to Wellgistics, 50% to PharmTech; term is 36 months unless earlier terminated.
Wellgistics makes preferred EBV pricing available immediately through EinsteinRx AI hub; expects revenue stream beginning Q2 2026.
EBV market forecast to grow from $2.39B in 2025 to $3B in 2030 per The Business Research Company.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Wellgistics Health, Inc. entered into Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC (effective 2026-03-06).

Action: entry
Agreement: collaboration
Counterparty: Kare PharmTech LLC
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC

View on SEC.gov

84 material agreements filed in the last 30 days. Browse all material agreements →

Wellgistics Health, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-009702

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.